MIBO stands for Minimum Information for studies reporting Biologics. The MIBO guidelines were developed to alleviate the problems arising from inadequate reporting of studies evaluating biological therapies, principally platelet rich plasma and mesenchymal stem cells.
Who should use MIBO?
Authors: MIBO aims to help authors to help improving the reporting of studies evaluating biologics in orthopaedics and will increase experimental transparency and repeatability, promote consitency and comparability, while encouraging standardization and the wider collaborative effort.
Peer reviewers and editors: MIBO may also be useful for critical appraisal of studies evaluating biologics.